UPDATE OF CYTOGENETIC AND MOLECULAR RESPONSE IN 88 ELDERLY PH+ CHRONIC MYELOID LEUKEMIA PATIENTS ENROLLED IN THE PHASE II EXPLORATIVE STUDY OF INTERMITTENT IMATINIB (IM) TREATMENT (INTERIM)